US 12274735
IL-4-fusion formulations for treatment of central nervous system (CNS) tumors
granted A61KA61K38/164A61K38/2026
Quick answer
US patent 12274735 (IL-4-fusion formulations for treatment of central nervous system (CNS) tumors) held by Medicenna Therapeutics Inc. expires Mon Apr 10 2045 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- Medicenna Therapeutics Inc.
- Grant date
- Tue Apr 15 2025 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Apr 10 2045 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 20
- CPC classes
- A61K, A61K38/164, A61K38/2026, A61K47/42, A61K47/46